Home
About
Pricing
Log In
Back
AVH
Asset Logo

Avita Medical Inc.

🇦🇺 ASX

🧬 BIOTECHNOLOGY

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🍃 Esg

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

-15.27%
Annual Growth

5 years average annual capital growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

30
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 260 full-time employees. The company went IPO on 2012-03-18. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

📈 Performance

Price History

+1959.92%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🍃 Environmental, Social and Governance scores ℹ️

🌳

Environmental Score
46

A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution

🕊️

Social Score
65

An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.

⚖️

Governance Score
23

An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.

🤓 Advanced information

Technical Info

💰 Price*

$1.66

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in AVH

30

📊 Total Capital Earnings

$19K

🔃 Average investment frequency

31 weeks

💵 Average investment amount

$2,342

Last time a customer invested in AVH

11 days
AVH investor breakdown
💵 Income of investors

More than 200k

6%

150k - 200k

8%

100k - 150k

25%

50k - 100k

31%

Less than 50k

28%
👶 Age of investors

18 - 25

26 - 34

37%

35 - 90

60%
🙋 Legal gender of investors

Female

30%

Male

70%

Pearlers who invest in AVH also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

🙌 Performance (5Yr p.a)

9.45%

📊 Share price

$111.56 AUD

🇦🇺 AUSTRALIA

💸 FINANCIALS

🧱 MATERIALS

⛳️ DIVERSIFIED

📈 HIGH PRICE GROWTH

Find Out More

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

🙌 Performance (5Yr p.a)

18.14%

📊 Share price

$151.91 AUD

🌏 GLOBAL

🤖 TECHNOLOGY

⛳️ DIVERSIFIED

📈 HIGH PRICE GROWTH

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

🙌 Performance (5Yr p.a)

23.41%

📊 Share price

$67.97 AUD

📈 HIGH PRICE GROWTH

🇺🇸 UNITED STATES

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

🙌 Performance (5Yr p.a)

8.18%

📊 Share price

$74.15 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

📈 HIGH PRICE GROWTH

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.

🙌 Performance (5Yr p.a)

-5.63%

📊 Share price

$207.79 AUD

⚖️ HIGH GOVERNANCE

🕊️ SOCIALLY AWARE

🧬 BIOTECHNOLOGY

Want more shares? Try these...

AVHDA

📊 Share price

$4.55 AUD

AVGDA

📊 Share price

$0.79 AUD
Compare
Add to watchlist